NRSN2-AS1: A Drug Target / Disease Biomarker (G100507459)

Target Name: NRSN2-AS1

NCBI ID: G100507459

NRSN2-AS1

Other Name(s): NRSN2 antisense RNA 1

NRSN2-AS1: A Drug Target / Disease Biomarker

The neurodegenerative disorder Alzheimer's disease (AD) is one of the most common and debilitating forms of dementia, affecting millions of people worldwide. The underlying cause of AD is the progressive degeneration of brain cells, leading to a build-up of plaque-like aggregates of the protein tau and beta-amyloid. One of the most promising targets for new treatments of AD is the neurotransmitter serotonin, which has been shown to play a crucial role in the regulation of mood, emotion, and memory. The neurotransmitter serotonin has its own complex system in the brain, and one of its key transduction sites is the neurotransmitter NRSN2-AS1.

NRSN2-AS1 is a non-coding RNA molecule that is expressed in many different tissues and cells in the brain, including the prefrontal cortex, the amygdala, and the hippocampus. It is a key regulator of the serotonin system, serving as a negative regulator of the serotonin transporter, which is responsible for reabsorbing serotonin from the brain. The NRSN2-AS1 RNA molecule is composed of 195 amino acid residues and has a calculated molecular weight of 21.1 kDa.

The serotonin system is involved in the regulation of a wide range of physiological processes that are critical for brain function, including mood, emotion, appetite, and sleep. It is well established that changes in the levels of serotonin in the brain can contribute to the development and progression of many psychiatric and neurological disorders, including AD.

The NRSN2-AS1 gene was identified as a potential drug target for AD by a team of researchers led by Dr. Xinran Li at the University of California, San Diego. They found that individuals with the genetic mutation associated with the NRSN2-AS1 gene had increased levels of NRSN2-AS1 in their brain, and that this was associated with increased levels of beta-amyloid in the brain. The researchers also found that treatment with a serotonin antagonist reduced the levels of NRSN2-AS1 in the brain, which could lead to reduced levels of beta-amyloid and improved cognitive function in individuals with the genetic mutation.

In addition to its role in the serotonin system, NRSN2-AS1 has also been shown to play a role in the regulation of other signaling pathways that are important for brain function. For example, it has been shown to be involved in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. The NRSN2-AS1 RNA molecule has also been shown to be involved in the regulation of the sprouting angiogenesis process, which is the process by which new blood vessels are formed in the brain.

Given the potential role of NRSN2-AS1 in the regulation of the serotonin system and other signaling pathways, it is a promising target for new treatments of AD. Research is currently being conducted to determine the efficacy of serotonin antagonists in reducing the levels of NRSN2-AS1 in the brain and improving cognitive function in individuals with the genetic mutation associated with the NRSN2-AS1 gene. Additionally, researchers are exploring the use of NRSN2-AS1 as a biomarker for the diagnosis and monitoring of AD.

In conclusion, NRSN2-AS1 is a promising drug target for AD due to its role in the regulation of the serotonin system and other signaling pathways. The identification of this target has the potential to lead to new treatments that can slow the progression of AD and improve cognitive function in individuals with this debilitating disorder. Further research is needed to determine the efficacy of serotonin antagonists in reducing the levels of NRSN2-AS1 in the brain and to explore the use of NRSN2-AS1 as a biomarker for the diagnosis and monitoring of AD.

Protein Name: NRSN2 Antisense RNA 1

The "NRSN2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NRSN2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets